Connect with us

Technology

Group14 Signs Agreements with Five Leading EV and CE Cell Manufacturers Supporting Global Electrification Efforts

Published

on

The five binding offtake agreements represent over $300 million of contract value

WOODINVILLE, Wash., June 4, 2024 /PRNewswire/ — Group14 Technologies, Inc., the world’s largest global manufacturer and supplier of advanced silicon battery materials, announces the signing of five multi-year binding offtake agreements amounting to a minimum commitment of over $300 million with three leading electric vehicle (EV) and two consumer electronic (CE) cell manufacturers across Europe, Asia, and North America. These strategic supply agreements continue to demonstrate Group14’s progress in driving the global adoption of next-generation silicon battery technology.

The agreements will allow Group14’s customers to deliver the highest performance batteries in production today to a diverse array of industries, including automotive, CE, electric vertical take-off and landing (eVTOL), and other markets. This reflects the broad applicability and high demand for Group14’s breakthrough silicon-carbon anode material, SCC55®. This material is engineered to deliver superior energy density, faster charging times, and greater overall efficiency compared to traditional graphite and silicon oxide-containing anodes and reduces the carbon footprint for its customers.

“The pace at which our customers are signing up for SCC55® deliveries confirms that since the introduction of silicon batteries, we are at the tipping point for the transition to the electrification of everything,” said Group14 CEO and Co-Founder Rick Luebbe. “We are witnessing a surge in demand from the EV battery market due to the transformational performance improvement that can be delivered with silicon batteries powered by Group14.”

Group14’s full customer base has forecasted demand for SCC55® that is more than four times the company’s projected production capacity by 2027. As a result, Group14 is rapidly scaling its global manufacturing capabilities worldwide. The company’s advanced Battery Active Materials (BAM-1) factory has been manufacturing at the ton-scale since 2021. It has delivered shipments of SCC55® to more than 100 customers representing 95% of worldwide lithium-ion battery production. A second factory in Moses Lake, Washington, is planned to start production in 2024 and is expected to be the world’s largest for advanced silicon battery materials with an initial annual capacity of 4,000 tons of SCC55® or 20 GWh of silicon battery material. The first manufacturing module from Group14’s joint venture with SK, Inc. in South Korea is in the final stages of commissioning. It will have a nameplate manufacturing capacity of 2,000 tons of SCC55®, equivalent to 10 GWh of silicon battery capacity annually.  With 30 GWh of production capacity ramping up in the next year, Group14 will be the world’s first EV-scale mass producer of advanced silicon materials.

About Group14 Technologies
Founded to enable the electrification of everything, Group14 is the world’s leading commercial manufacturer and supplier of silicon battery technology. Today, Group14 is working with more than 100 customers globally, which represent 95% of worldwide lithium-ion battery production. Group14 operates a commercial-scale Battery Active Materials factory, BAM-1, in Woodinville, WA, and recently launched a joint venture factory with SK in South Korea. A second U.S. factory, BAM-2, in Moses Lake, WA, is expected to be completed in 2024. To date, Group14 has raised over $650 million in financing from investors and customers such as Porsche AG, Microsoft Climate Innovation Fund, OMERS, Lightrock Climate Impact Fund, Decarbonization Partners, Amperex Technology Limited (ATL), BASF, Resonac and SK Inc. Visit us at www.group14.technology.

View original content to download multimedia:https://www.prnewswire.com/news-releases/group14-signs-agreements-with-five-leading-ev-and-ce-cell-manufacturers-supporting-global-electrification-efforts-302162657.html

SOURCE Group14 Technologies

Continue Reading

Technology

Infinitus Launches FieldForce to Extend the Reach of Pharmaceutical Sales and Reimbursement Teams

Published

on

By

AI agent solution helps field teams become AI first, preparing for HCP meetings, staying connected between visits, and extending provider and reimbursement support without adding additional headcount

SAN FRANCISCO, Oct. 7, 2026 /PRNewswire/ — Infinitus, healthcare’s agentic communications platform, today announced FieldForce, a new set of secure AI agents designed to extend the capacity of pharmaceutical field teams. Pharma companies can deploy FieldForce to support sales representatives, field reimbursement managers (FRMs), or both, depending on the needs of their organization. For both roles, FieldForce enables teams to become AI-first, using AI agents to extend their capacity across activities before, after, and in between HCP interactions. Importantly, it gives pharmaceutical companies another way to support more providers while giving HCPs access to information and assistance between field visits that can help them better serve their patients.

Pharmaceutical companies are under growing pressure to increase commercial productivity while managing costs. A May 2026 analysis from Deloitte found that sales representatives spend roughly two-thirds of their workday on activities such as research, product and prescribing information, scheduling, and administrative work, leaving less than one-third for customer interactions.

The pressure to do more with existing resources is also playing out across the industry. One recent analysis found that the 17 largest pharmaceutical companies collectively reduced their workforces by more than 22,000 employees in 2025, as companies looked to improve efficiency and prepare for patent expirations and other market pressures. FieldForce is specifically designed to help organizations like these extend field capacity without requiring a corresponding increase in headcount.

Supporting sales and reimbursement teams around HCP interactions

FieldForce gives sales representatives and FRMs agentic support to help manage the work around HCP interactions. The agents connect with field teams’ CRMs to pull together information for preparation before a meeting, capture notes, and update systems afterward. Additional FieldForce agents can be available for inbound calls 24/7 to support providers by answering questions between visits.

For FRMs, AI agents can answer questions about prior authorization status, claims and reimbursement, and help onboard provider offices with approved access materials. Across these interactions, Infinitus Lens provides same-day compliance monitoring and surfaces trends and insights, such as: prescribing trends per provider or provider tier; emerging question themes or support topics; and recommendations for proactive and compliant content or education that can be shared.

Extending provider reach without adding field headcount

FieldForce is also designed to help pharmaceutical companies support providers who may not have regular contact with a sales representative or FRM. A dedicated AI agent can be available between visits, giving providers a direct path to information and support when a field team member is unavailable. For HCPs, that can mean more timely access to information and reimbursement support as they work to help patients access and navigate their treatment. For pharmaceutical companies, it can expand coverage across a larger provider population without requiring a corresponding increase in field hires.

“Our pharma customers need their field teams to cover more providers while managing significant cost and productivity pressures,” said Ankit Jain, CEO and co-founder of Infinitus Systems. “They’re also seeing that the companies embracing AI are finding new ways to scale and operate more efficiently, making an AI-first approach increasingly essential to staying competitive. FieldForce gives sales and reimbursement teams AI support across the work that happens before, after and in between HCP interactions, extending their capacity so they can spend more of their time on the relationships and issues that require their attention.”

Connecting commercial and medical conversations safely

Infinitus FieldForce is built around the distinction between promotional and medical communications within pharmaceutical organizations. The sales agent can support appropriate promotional conversations with HCPs. When a provider asks a clinical or safety question that falls outside the sales representative’s role, the agent can hand the conversation off to a member of the organization’s Medical Information team along with full context. This gives HCPs a direct path to the appropriate resource while helping sales representatives stay within their role.

Built for pharmaceutical organizations

FieldForce brings Infinitus’s trusted, healthcare-native AI to power internal tools for the first time. AI agents are trained on specific data and resources provided by each individual pharma organization along with Infinitus’s proprietary knowledge graph that leverages historical data from millions of payor interactions. This gives pharmaceutical leaders a consistent source of approved information across provider engagement and reimbursement workflows, while providing a way to measure the impact of AI through metrics such as provider coverage, interactions, and cost per interaction.

In July, Infinitus announced its AI-first, human-backed hub solution, designed to streamline patient, provider, and payor communications traditionally managed through legacy call-center infrastructure. FieldForce extends Infinitus’s AI agent capabilities into pharmaceutical commercial and market access teams, giving sales representatives and FRMs around-the-clock support while helping HCPs get timely answers and support to help patients.

About Infinitus

Infinitus is healthcare’s agentic AI communications platform, coordinating conversations and workflows across providers, health plans, specialty pharmacies, pharmaceutical manufacturers, and patients to make sure care reaches those who need it. Infinitus’s system combines industry-leading safety guardrails with the largest dynamic knowledge graph built on millions of real-world interactions. The company has raised over $100M from investors including Google Ventures, Kleiner Perkins, Andreessen Horowitz, and Coatue. Infinitus was recently named to Fast Company’s World’s Most Innovative Companies and is trusted by over 50% of the Fortune 50 healthcare companies. Learn more at www.infinitus.ai

View original content to download multimedia:https://www.prnewswire.com/news-releases/infinitus-launches-fieldforce-to-extend-the-reach-of-pharmaceutical-sales-and-reimbursement-teams-302900497.html

SOURCE Infinitus Systems, Inc.

Continue Reading

Technology

JND AutoRedact™ Wins 2026 Relativity Innovation Award

Published

on

By

AutoRedact recognized for delivering redaction accuracy at scale inside Relativity aiR.

SEATTLE, Oct. 7, 2026 /PRNewswire/ — JND Legal Administration, the U.S. leader in legal management and administration services, announced that its AutoRedact™ AI-assisted redaction tool has received the Relativity Innovation Award in the Act category at Relativity Fest 2026, the premier event in the eDiscovery industry. The Act Award honors solutions that enhance Relativity’s redaction, quality control, reporting, case strategy, or production features, delivering meaningful results.

AutoRedact uses both AI and deterministic rules to find and redact sensitive information like personal data or privileged content within images stored in Relativity aiR (formerly RelativityOne). Legal teams describe in plain language what needs to be redacted, iterate and test the results on sample documents in the Detector Lab, and then apply the calibrated instructions at scale across their document populations. AutoRedact also has a dedicated detector for data subject access requests (DSARs) that redacts personal and sensitive information while keeping the requesting individual’s own data visible, a common and time-consuming challenge in privacy compliance. AutoRedact provides confidence levels for redactions to assist legal teams with focusing their human QC efforts and every redaction can be reviewed and adjusted before documents are produced.

“I’m incredibly grateful to our team, whose expertise and relentless testing made AutoRedact possible,” said Ben Sexton, Senior Vice President of Innovation and Strategy at JND. “We’re excited about what AutoRedact can do for our clients.”

“Innovation at JND has always meant building tools that deliver real, measurable results,” said Jennifer Keough, CEO and Co-Founder of JND. “AutoRedact reflects the ingenuity and dedication of our team, and this award is a testament to their work. We congratulate everyone who made it possible.”

Headquartered in Seattle, JND continues to solidify its status as the industry leader in end-to-end eDiscovery solutions. Its eDiscovery service line supports corporations, law firms, and government agencies in deploying the best solutions and technology to meet their goals using Relativity aiR, the market’s leading cloud-based technology solution. JND is one of only two Relativity Platinum Provider Partners.

This award marks JND’s second Relativity Innovation Award in three years. In 2024, Ben Sexton received the Relativity Innovation Award in the Artificial Intelligence category for his leadership in the adoption and development of generative AI tools in eDiscovery. JND’s team also includes three Relativity AI Visionary award recipients.

To schedule a demo of AutoRedact, contact autoredact@jndla.com.

About JND Legal Administration

JND eDiscovery, a RelativityOne software reseller and a division of JND Legal Administration, a Sedgwick company, is the nation’s foremost legal services and settlement administration solutions provider. JND’s fully-featured Relativity aiR instance and professional services team support a broad network of plaintiff and defendant law firms, corporate legal departments and government agency clients in future-proofing their eDiscovery systems. For more information, visit https://www.jndla.com/ediscovery.

Media Contact:
Joe Sexton
info@jndla.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/jnd-autoredact-wins-2026-relativity-innovation-award-302900438.html

SOURCE JND Legal Administration

Continue Reading

Technology

L8P8 Launches Tru8 Connect, Free Messaging That Uses Usernames Instead of Phone Numbers

Published

on

By

Messages are end-to-end encrypted, kept only on users’ phones and deleted after eight days

GLENDALE, Calif., Oct. 7, 2026 /PRNewswire/ — L8P8 Inc. today launched Tru8 Connect, a free messaging feature inside the Loop8 app for iOS and Android. People on Tru8 Connect find each other by username, so neither person ever sees the other’s phone number.

Giving someone your number is a bigger step than it used to be. A phone number can lead to your name, your address and the accounts tied to it. Once you hand it out, you can’t take it back. On Tru8 Connect, if a conversation goes badly, you block the person and that’s the end of it. They never had your number in the first place.

Messages are end-to-end encrypted. Loop8’s servers pass them along but can’t read them, and they delete each message once it’s delivered. After that, the message exists only on the two phones in the conversation, and opening it takes Face ID or a fingerprint. Every message deletes itself eight days after it’s sent.

When the app detects a screenshot or screen recording of a chat or a shared photo, it alerts everyone in the conversation and shows who took it.

“People think twice before giving a stranger their phone number, and they should,” said Zarik Megerdichian, founder and CEO of L8P8. “With Tru8 Connect, you don’t have to. And since we delete messages once they’re delivered, there’s no pile of old conversations sitting on our servers for someone to break into later.”

Tru8 Connect is open to users 16 and older. It’s available now in the Loop8 app, which is free on the App Store and Google Play. Loop8 also includes a password manager and an authenticator, both unlocked with biometrics instead of a master password.

About L8P8 Inc.
L8P8 Inc., based in Glendale, Calif., makes privacy and identity software that uses biometrics in place of passwords. Its products include Loop8, a consumer app, and Loop8ID, an age verification and identity platform for businesses. Learn more at loop8.ai and loop8id.com.

Media Contact
Zarik Megerdichian
L8P8 Inc.
pr@l8p8.com
‪(818) 208-0238‬

View original content to download multimedia:https://www.prnewswire.com/news-releases/l8p8-launches-tru8-connect-free-messaging-that-uses-usernames-instead-of-phone-numbers-302897892.html

SOURCE L8P8 Inc.

Continue Reading

Trending